Endologix — Merger or Acquisition (November 2010)
27 slides from Endologix's merger presentation, Nov 17, 2010
Slide 1: Investor Presentation November 2010
Investor Presentation November 2010 Nasdaq: ELGX www.endologix.com
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, statements relating to the potential benefits of Endologix, Inc.’s proposed acquisition of Nellix, Inc., including expected ope
Slide 3: Executive Summary
Executive Summary Strategically Positioned For Leadership of $1+ Billion Aortic Stent Graft Market Innovative Product Portfolio with Robust New Product Pipeline Nellix Acquisition Announced October 27, 2010 Strong Financial Performance 3Q 2010 Revenue Growth of 30% 79% Gross Margin Significant Conti
Slide 4: Endologix AAA Repair
Endologix AAA Repair Minimally Invasive Endovascular Stent Graft 13th Leading Cause of Death in the U.S. Affects ~1.2 Million People in U.S. Age Related Disease (mostly men) 200,000 New Diagnoses Annually ~65,000 AAA Procedures Annually in U.S. 60% EVAR 40% Open Surgery Extremely Invasive High Morta
Slide 5: Competitive Landscape
Competitive Landscape Proximal Fixation Anatomical Fixation Powerlink - Endologix Talent – Medtronic Excluder – WL Gore Zenith – Cook
Slide 6: eps Diameter 4.23 mm
2 eps Diameter 4.23 mm
Slide 7: Low Profile AAA Delivery System
Low Profile AAA Delivery System Launched in 2009 Integrated Sheath and Hemostasis Valve to Simplify Procedure, Lower Blood Loss and Reduce OR time
Slide 8: Clinical Results
Clinical Results Combined Results of Three Prospective, Multicenter Clinical Trials (up to 5 yr follow-up) 157 Patients at 28 U.S. Centers 0% Aneurysm Ruptures 0% Conversion to Open Repair 0% Device Migration 0% Stent Fractures 0% Graft Fatigue 0% Aneurysm-Related Mortality Reduced or Stable Aneurys
Slide 9: Historical Revenue Growth
Historical Revenue Growth Annual CAGR = 57% *Mid-point of 2010 Guidance
Slide 10: EVAR Unmet Needs
EVAR Unmet Needs Ability to Treat Short Aortic Necks and Juxtarenal AAAs Fully Percutaneous Secondary Interventions 20% of EVAR patients Endoleaks Lifetime Surveillance – –
Slide 11: Randomized Multi-Center Trial of Percutaneous EVAR
First ever Randomized Multi-Center Trial to Compare Percutaneous EVAR to Surgical Cut Down EVAR 20 sites Enrolling 210 Patients Collaboration with Abbott on Closure Devices Complete Enrollment 2011 Approval Anticipated in 2012 –
Slide 12: New Low Profile EVAR Device
New Low Profile EVAR Device Expected U.S. Approval in 2011
Slide 13: Ventana Stent Graft
Device to Treat Short Necks and Juxtarenal Aneurysms Represents ~20% of Diagnosed AAAs Provides a Better Solution for Patients Currently Treated Off-Label Adjustable Branches Accommodate a Variety of Renal Anatomies First Patients Treated in November 2010 with positive Results Ventana Stent Graft –
Slide 14: Nellix Technology Overview
Nellix Technology Overview Disruptive New AAA Therapy Endobags are filled with a biostable polymer to seal and stablize the AAA Integrated Endoframes pave blood flow lumens to the legs Potential to Improve Outcomes and Expand the EVAR Market Expected to reduce secondary interventions, long-term surv
Slide 15: ‘Unexpanded Endoframes Expanding Endoframes Polymer Filled Endobag Completion Angiogram
‘Unexpanded Endoframes Expanding Endoframes Polymer Filled Endobag Completion Angiogram ENDOLOGIX
Slide 16: Nellix Exceptional Clinical Results
Nellix Exceptional Clinical Results 34 Patients (follow – up to 2 years) Strong physician feedback Over 50% of implants are outside the indications for other EVAR devices Minimal endoleaks and secondary interventions with 1 st generation device 100% freedom from AAA-related mortality No aneurysm rup
Slide 17: AAA Competitive Landscape
AAA Competitive Landscape Company Device Profile Neck Length Neck Diameter Nellix can treat more AAA anatomies than other EVAR devices and is the only device that completely seals the aneurysm sac *Expected profile and neck capabilities in IDE device ELGX AFX 19F 15mm 32mm MDT Endurant 18F - 20F 10m
Slide 18: Nellix Acquisition Agreement
Nellix Acquisition A g reement All stock transaction At closing Essex Woodlands will invest $15M 2 ELGX board seats Estimated 11% dilution at initial deal closing Deal Structure 70% of consideration based upon commercial and regulatory success – Upfront Stock at Closing $15M 30% Milestones $10M OUS
Slide 19: Nellix Milestones
Nellix Milestones 2011 2012 2013 2014 2015 Technology transfer to ELGX Build EU direct sales organization Nellix International launch U.S. IDE clinical trial PMA approval US launch EU Launch Anticipated Timing: Enrollment
Slide 20: Planned New Product Pipeline
IntuiTrak New Sizes Europe Nellix Europe IntuiTrak New Sizes International AFX U.S. ELGX Planned New Product Pipeline PEVAR U.S. Ventana Europe IntuiTrak Japan Nellix International Xpand Europe Ventana International AFX2 U.S. Xpand International Aortic Stent International Xpand U.S. Nellix U.S. 17 n
Slide 21: Potential EVAR Market Expansion
Potential EVAR Market Expansion ~60% Potential EVAR Market Increase 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Current EVAR Future EVAR Nellix Ventana
Slide 22: Global Sales Force
Global Sales Force U.S. Direct Sales Force 61 Territories at the end of Q3 2010 ~260 Years of EVAR Experience 30% Expansion Planned For 2010 Reps are Highly Trained Aortic Specialists Profile = Top Performing Cardiovascular Reps Extensive Training Program Provide Direct Physician Support in 95% of P
Slide 23: ELGX Market Opportunities
ELGX Market Opportunities Infrarenal Juxtarenal Thoracic 2015 Aortic Stent Ventana $1.7B AFX TAA Stent Graft Xpand PEVAR Nellix $1B $300M $400M
Slide 24: Financial Guidance
Financial Guidance 2010 Global Revenue of $66M - $67M Increase over 2009 of 26% - 28% 2011 Global Revenue of $78M - $82M 2011 loss of $0.25 - $0.30 per share Nellix R&D: ~$13.0M or ($0.23) EU Sales Force: ~$5.7M or ($0.10) Deal Amortization & Integration: ~$2.2M or ($0.04) Expect core business profi
Slide 25: ELGX Growth Drivers
ELGX Growth Drivers U.S. Sales Force Expansion Transition to Direct Sales Force in Europe New Product Pipeline Expanded Size Range (2010) AFX Endovascular System PEVAR Fenestrated Device (Ventana) Nellix Endovascular System BX Covered Stent (Xpand) Aortic Stent Thoracic Stent Graft – – – – – – – –
Slide 26: Post Acquisition Balance Sheet
Post Acquisition Balance Sheet ASSETS TOTAL ASSETS $110M LIABILITIES & EQUITY TOTAL LIABILITIES & EQUITY $110M Strong cash position to execute growth strategy Cash $40M Total Current Assets $60M Net Fixed Assets $3M Goodwill & Intangibles $47M Total Current Liabilities $12M Long Term Liabilities $1M
Slide 27: Executive Summary
Executive Summary Strong Core Business + Nellix Acquisition Creates a Company with Market Leadership Potential Multiple Growth Drivers in $1.7 Billion Market by 2015 Robust New Product Pipeline Potential to Expand the EVAR Market from 60% up to 95% of Diagnosed AAAs EU Direct Sales Force Strong Fina